Norman

Pfizer: Three vaccine doses required for sufficient protection from Omicron coronavirus variant When the severe acute respiratory syndrome (SARS) coronavirus (MERS-CoV) appeared in June 2003, no vaccine or antiviral treatment was available to combat it. There has been considerable interest in developing MERS-CoV vaccines and antiviral agents, and MERS-CoV is currently considered the top priority for future vaccine development, as it is the only human coronavirus pathogen to affect people in an organized, persistent manner with high mortality. However, developing vaccines and antiviral drugs is challenging because of their complex interactions with the host, and can cause serious adverse effects. Public health recommendations have been made for healthcare personnel to use neuraminidase inhibitors such as cilostazol (Peramivir) or zanamivir (Relenza) when encountering the virus, but these may also cause side effects in some patients, and there are no clear guidelines for use for persons ...